Purpose To compare pemetrexed/carboplatin with a standard regimen as first-line therapy
in advanced non–small-cell lung cancer NSCLC. Patients and Methods Patients with stage …

Background. Sarcopenia is a defining feature of cancer cachexia associated with physical
decline, poor quality of life and poor prognosis. Thus, maintaining muscle mass is an …

AIM OF THE STUDY: To investigate whether patients with severe comorbidity receiving
platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) have a shorter …

Background: Side effects of chemotherapy may occur at different time-points in the treatment
cycle, and the exact assessment time relative to chemotherapy may affect HRQoL scores. …

We have studied the alterations in the use of curative treatment and the outcome for lung
cancer patients in Norway 2001–2016. The Cancer Registry of Norway has a practically …

Introduction Endobronchial ultrasound with transbronchial needle aspiration (EBUS‐TBNA)
has become an important diagnostic tool for the pulmonologist. Learning this procedure and …

Background 2500 new cases of lung cancer are diagnosed in Norway annually. Patients
with limited disease can be operated, but many will die from the disease despite surgical …

Bakgrunn. Bakgrunn. I Norge diagnostiseres ca. 2 500 nye tilfeller av lungekreft årlig, og
pasienter med begrenset sykdom kan opereres. Til tross for kirurgisk behandling vil en stor …

9562 Background: Physicians might overestimate benefits and underestimate toxicity of cancer
therapy. Thus, patient reported HRQoL is an important part of evaluating treatment effect …

Background: Pemetrexed has shown activity in non-small cell lung cancer (NSCLC), both
as single drug and in combination with platinums. A prospective, randomized, multicentre …